Deal Struck for License of Drug Delivery System for Lucentis Developed by Surmodics

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Roche and Genentech Strike Deal With Surmodics For Biodegradable Microparticle Drug Delivery System for Lucentis

Posted By Irv Arons On October 7, 2009 @ 6:52 am In Industry News,Macular Degeneration,New Technologies,Research,Retina | Comments Disabled

Roche and Genentech have signed a licensing agreement with SurModics, Inc., to take advantage of SurModics’ proprietary biodegradable microparticle drug delivery system, to develop and commercialize a sustained delivery formulation for Lucentis in treating age-related macular degeneration. The agreement also provides Roche and Genentech with the opportunity to develop additional compounds using the sustained drug delivery system for the treatment of other ophthalmic diseases.

For the full story, see the SurModics news release ^[1].

Also, for more on this, see my new writeup ^[2] in my online Journal.

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/002298-roche-and-genentech-strike-deal-with-surmodics-for-biodegradable-microparticle-drug-delivery-system-for-lucentis/

URLs in this post:

[1] SurModics news release: http://tinyurl.com/yatd85e

[2] my new writeup: http://tinyurl.com/AvastinUpdate28

Click here to print.